US patent
These patent grants are important as they underpin ongoing investment in clinical development of efti and allow us to confidently engage in business development discussions,” said Marc Voigt, CEO of Immutep.
The claims of this new patent build on the protection provided by the parent patent, and are directed to methods of treating cancer by administering Immutep‘s lead active immunotherapy candidate eftilagimod alpha (“efti” or “IMP321”) and a PD-1 pathway inhibitor. Again, according to the claims, the PD-1 pathway inhibitor is either pembrolizumab or nivolumab. The expiry date of the patent is 20 January 2036
Merck or BMS ?
Ann: Immutep granted US patent for IMP761 agonist LAG-3 antibody, page-21
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 41.0¢ | 38.5¢ | $1.351M | 3.389M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16911 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 154170 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |